Top five pharma companies saw overall decline in Q3 2019
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
List view / Grid view
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
Xyphos Biosciences will become a wholly owned subsidiary of Astellas Pharma following an acquisition made by the latter company.
Novartis, Merck and Allergan have joined numerous other pharmaceutical companies by increasing the price of certain drugs since the start of 2020.
Drug makers have hiked the price of over 250 drugs in the US so far in 2020, according to new reports.
A new report from the FDA has shown that greater competition among generic drug makers is associated with lower generic drug prices.
Driven by the launch of various pipeline agents, a new report has projected that the multiple sclerosis therapeutics market will reach $32.9 billion in 2028.
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
Top pharmaceutical companies have reduced their drug costs in China by an average of 61 percent, to be added to the reimbursement list in the country.
The content sessions at CPhI Worldwide have revealed the coming trends that the pharmaceutical industry will see next year.
The M&A between Novartis and The Medicines Company will add inclisiran, the potentially first-in-class treatment to reduce cholesterol, to the former’s pipeline.
According to a new report, the UK is leading the rest of Europe for early-stage clinical research into new medicines and vaccines, with more than 600 commercial clinical trials taking place in the NHS.
US Speaker Pelosi’s new drug pricing plan could impact small biotech companies, reducing their innovation by 90 percent, says new research.
After regulatory approval, Bristol-Myers Squibb has announced its successful acquisition of Celgene, completing the merger.
A new report has found that even though ambitions are high in the healthcare sector to invest in digital initiatives, the rate of implementing these initiatives are low.